News | Ventricular Assist Devices (VAD) | September 18, 2015

SynCardia Systems Issues Class I Recall of Freedom Driver System

Part failure on drive mechanism for Total Artificial Heart could cause device to stop pumping, resulting in serious injury or death

Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

September 18, 2015 — SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total Artificial Heart (TAH-t) on Aug. 6, 2015. The recall focused on a specific part of the Freedom Driver drive mechanism that the company said may fail and cause the device to stop pumping.

The SynCardia TAH-t is a mechanical replacement for a patient’s heart, used in patients at risk of imminent death from heart failure who are waiting for a heart transplant. It is a pump that is implanted into the chest to replace the bottom half of a patient’s heart (left and right ventricles). The device is sewn to the remaining top half of the patient’s heart (atria). The Freedom Driver system is attached to the TAH-t pump and operates and monitors the device.

SynCardia noted that patients do not receive any advance warning that the device may fail. If it does fail, a red light located in the center of the driver, toward the top, will stay red and a loud continuous alarm will sound.

However, if the Freedom Driver stops pumping, the patient will lose consciousness almost immediately, which means that the warning light and alarm may not be helpful. The patient will likely experience serious injury or death if not immediately switched to a backup driver by a caregiver.

In the Urgent Medical Device Recall Letter, SynCardia told customers they would notify all hospitals that have the affected drivers — in lot numbers 85978 (serial numbers 85978-001 through 85978-040) and 85979 (Serial Numbers 85979-001 through 85979-040) — and replace the drivers with new ones. Additionally, SynCardia informed customers to:

  • Notify any patients with an affected device and exchange the driver;
  • A SynCardia representative will assist with replacement and return of the product; and
  • Return affected Freedom Drivers and complete the Recall Acknowledgement and Receipt Form attached to the letter.

For more information: www.fda.gov/medwatch

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init